| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | -0.027 | 0.6 |
| mRNA | ISOX | CTRPv2 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | BRD-K35604418 | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | BRD-K34099515 | CTRPv2 | pan-cancer | AAC | -0.15 | 0.6 |
| mRNA | masitinib | GDSC1000 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | AZD4547 | CTRPv2 | pan-cancer | AAC | 0.022 | 0.6 |
| mRNA | navitoclax:pluripotin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | GW 441756 | GDSC1000 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | QL-XII-61 | GDSC1000 | pan-cancer | AAC | 0.025 | 0.6 |
| mRNA | BMS-754807 | GDSC1000 | pan-cancer | AAC | 0.019 | 0.6 |